Vericel Corp (VCEL) Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Vericel Corporation NASDAQ:VCEL Healthcare · Biotechnology
Mkt Cap $2.06B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026
Vericel will report third quarter 2026 financial results on Thursday, November 5, 2026.
Management will host a conference call and webcast at 8:30 a.m. ET the same day, with slides and a one-year replay available on the investor relations site.
This is a scheduling notice only; no results or guidance were disclosed.
• 10d ago AI analysis › Press Release ⚠ 4
Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.
This GlobeNewswire item is a paid promotional commentary by Wall Street Investor whose featured subject is Conexeu Sciences (CNXU), not the filer Axogen.
Axogen appears only as sector context: Q2 2026 revenue of $69.7 million, up 23.1%, with Breast segment growth above 50% and FY2026 guidance raised to at least $279 million.
The disclaimer confirms the publisher was compensated to promote Conexeu and that Axogen and other named companies are 'not peers, competitors, or financial comparables' and not involved in the article.
• 26d ago AI analysis › Press Release ⚠ 2
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
MediWound received an additional $3.3 million in non-dilutive funding from the U.S. Department of War to advance a room-temperature-stable formulation of NexoBrid as a non-surgical debridement solution for battlefield burn care.
The award raises the total program budget to $21.8 million and supports development through an IND submission to the FDA, with work focused on completing CMC, establishing in-house cGMP manufacturing, and producing clinical batches.
The program falls within MediWound's existing North American license agreement with Vericel, which holds exclusive commercial and development rights to NexoBrid in the region.
• 1mo ago AI analysis › Press Release
Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026
Vericel Corporation will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026.
A webcast of the presentation will be available on the investor relations section of the Vericel website, so investors can follow the remarks remotely.
The release contains no new financial, clinical, or regulatory information; it is a routine scheduling notice. Vericel markets three products in the U.S. -- MACI for knee cartilage repair, Epicel for severe burns, and NexoBrid under exclusive North American license from MediWound.
• 1mo ago AI analysis › Press Release ⚠ 3
Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
Axogen reported Q2 2026 revenue of $69.7 million, up 23.1% year-over-year, surpassing the consensus of $68.4 million driven by over 50% growth in the breast reconstruction segment.
Despite raising full-year guidance to at least $279 million, the company's adjusted earnings of $0.12 per share missed consensus and gross margins dipped to 72.7%.
The commentary notes Axogen as a commercial-stage proof point for regenerative medicine in reconstructive surgery, though the article itself is a paid promotion for another entity.
• 2mo ago AI analysis › Press Release ● Critical
Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program
Vericel reported Q2 revenue of $77.5 million, up 22% year-over-year, driven by 23% growth in MACI revenue to $65.5 million.
The company achieved net income of $2.2 million, or $0.04 per share, compared to a net loss in the prior year, and generated $14.3 million in free cash flow.
Vericel raised full-year 2026 revenue guidance to $330-$340 million and authorized a $200 million share repurchase program.
• 3mo ago AI analysis › Press Release
Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
Vericel announced it will report second quarter 2026 financial results on Thursday, July 30, 2026.
Management will host a conference call and webcast at 8:30 a.m. ET to discuss the results and business highlights.
A replay of the webcast will be available on the company's investor relations website.
• 3mo ago AI analysis › Press Release ⚠ 3
Regenerative Medicine’s Next Chapter: Inside the Race to Make the Body Rebuild Itself
This sector analysis, issued on behalf of Conexeu Sciences Inc., forecasts the regenerative medicine market growing to over US$100 billion within a decade, driven by demographic trends and advancements in tissue engineering.
Conexeu is described as an early-stage, pre-revenue company utilizing a proprietary collagen-based ECM platform known as CXU™, having commenced trading on the Nasdaq in May 2026.
The article compares Conexeu to established public peers like Integra LifeSciences and Vericel, while cautioning investors regarding the regulatory and reimbursement risks inherent in the sector.
• 4mo ago AI analysis › Press Release ⚠ 3
The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
Conexeu Sciences reports transferring standardized formulation methods to its CDMO and advancing manufacturing scale-up activities for its lead wound-care device candidate.
The company is preparing a 510(k) premarket notification targeted for the first quarter of 2027, supported by prior FDA pre-submission feedback through the Q-Submission process.
Development of the CXU™ platform includes a preclinical breast matrix program in collaboration with Wake Forest Institute for Regenerative Medicine, targeting broader applications beyond wound care.
• 4mo ago AI analysis › Press Release
Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026
Vericel Corporation will present at the 2026 Truist Securities MedTech Conference on June 16, 2026.
A webcast of the presentation will be available on the company's Investor Relations website.
The release includes standard boilerplate descriptions of Vericel's product portfolio, including MACI, Epicel, and NexoBrid.
• 4mo ago AI analysis › Press Release ● Major
Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
Vericel delivered a strong Q1 with total revenue increasing 30% year-over-year to $68.4 million, fueled by 91% growth in Burn Care revenue and solid MACI performance.
Management raised full-year 2026 revenue guidance by $10 million to a range of $326 million to $336 million, reflecting confidence in sustained demand.
The company achieved a cash generation inflection, reporting free cash flow of $15.1 million and holding approximately $211 million in cash and investments with no debt.
• 5mo ago AI analysis › Press Release
Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026
Vericel Corporation announced it will report its first-quarter 2026 financial results on Thursday, May 7, 2026.
Management will host a conference call and webcast at 8:30 a.m. ET to discuss the results and business highlights.
The company is a leader in advanced therapies for sports medicine and severe burn care markets.
• 6mo ago AI analysis › 
